# Insmed (INSM) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/INSM
## Company Profile
- Ticker: INSM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Respiratory
## Stock Data
- Close: 132.57 USD
- Market cap: 22483731742.23 USD
- Last updated: 2026-08-11
## Business Overview
### Serious and Rare Diseases
Insmed develops and commercializes therapies for serious pulmonary and rare diseases. Its portfolio combines marketed respiratory medicines with late-stage inhaled therapies and earlier gene-therapy programs.
### Commercial Respiratory Portfolio
BRINSUPRI, or brensocatib, is a DPP1 inhibitor for non-cystic-fibrosis bronchiectasis. ARIKAYCE is an inhaled liposomal amikacin therapy for *Mycobacterium avium* complex lung disease.
### TPIP
Treprostinil palmitil inhalation powder is a long-acting inhaled prostanoid in Phase 3 development for pulmonary arterial hypertension, with additional programs planned in progressive and idiopathic pulmonary fibrosis.
### Earlier Pipeline
INS1033 is a second DPP1 inhibitor approaching the clinic, while INS1203 is a gene-therapy candidate for Stargardt disease.
## Why The Stock Is Moving

As of Aug 11, 2026, INSM closed down 1.62% at $132.57. No new same-company headline was identified in the current news window.

## Future Catalysts

- Japanese regulatory decision for brensocatib during 2026.
- TPIP Phase 2b open-label-extension data in the third quarter of 2026.
- Supplemental NDA submission for ARIKAYCE in the second half of 2026.
- IND filings for INS1033 and INS1203 during 2026.
- Initiation of a Phase 3 TPIP study in progressive pulmonary fibrosis by year-end 2026 and in idiopathic pulmonary fibrosis in the first half of 2027.

## Recent News
- 2026-08-06 11:00 EST — [Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/INSM/insmed-reports-second-quarter-2026-financial-results-and-provides-business-updat-e68db27f) — Source: Insmed
- 2026-07-23 11:00 EST — [Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026](https://biopharmsignal.com/news/INSM/insmed-to-host-second-quarter-2026-financial-results-conference-call-on-thursday-b4396c01) — Source: Insmed
- 2026-07-16 11:00 EST — [Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension](https://biopharmsignal.com/news/INSM/insmed-announces-positive-12-month-data-from-the-ongoing-open-label-extension-st-7880862e) — Source: Insmed
- 2026-06-23 11:00 EST — [Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory](https://biopharmsignal.com/news/INSM/insmed-appoints-samuele-butera-as-senior-vice-president-general-manager-global-r-5bfb9a1f) — Source: Insmed
- 2026-06-04 11:00 EST — [Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Insmed